Navtemadlin (KRT-232) is an MDM2 inhibitor currently being investigated in a clinical trial (NCT03787602) involving patients with p53 wild-type MCC, both as a monotherapy and in combination with avelumab (PD-L1 inhibitor) [4,27,28]. This evidence concerns the gene TP53 and Merkel cell skin cancer.